Merck spent $10bn on lung disease-focused biotech Verona Pharma in July, its biggest acquisition in two years, amid concerns ...
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
The equity of biotechnology firm Tempest Therapeutics continues to face severe downward pressure. Investor sentiment has been battered by a contentious acqui ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback